Published in Arch Pathol Lab Med on July 01, 2000
Centrosome amplification drives chromosomal instability in breast tumor development. Proc Natl Acad Sci U S A (2002) 3.81
Evaluation of the stage IB designation of the American Joint Committee on Cancer staging system in breast cancer. J Clin Oncol (2014) 2.73
An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat (2007) 2.65
Antibody-based enrichment of peptides on magnetic beads for mass-spectrometry-based quantification of serum biomarkers. Anal Biochem (2006) 2.55
Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res (2010) 2.33
Small cell neuroendocrine carcinoma of the breast: a report of three cases and review of the literature. J Clin Pathol (2005) 2.18
Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg (2002) 1.79
Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer. BMC Cancer (2008) 1.76
Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol (2004) 1.72
Gene expression signature in organized and growth-arrested mammary acini predicts good outcome in breast cancer. Cancer Res (2006) 1.69
Contralateral prophylactic mastectomy after unilateral breast cancer: a systematic review and meta-analysis. Ann Surg (2014) 1.50
Ratios of involved nodes in early breast cancer. Breast Cancer Res (2004) 1.50
HER2 gene status in primary breast cancers and matched distant metastases. Breast Cancer Res (2007) 1.45
Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX. J Clin Oncol (2013) 1.45
Comparison of visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer. Br J Cancer (2012) 1.44
MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer: correlations with prognostic factors. J Cell Mol Med (2006) 1.33
Effects of common germline genetic variation in cell cycle control genes on breast cancer survival: results from a population-based cohort. Breast Cancer Res (2008) 1.28
Do the derived neutrophil to lymphocyte ratio and the neutrophil to lymphocyte ratio predict prognosis in breast cancer? Int J Clin Oncol (2014) 1.27
Prognostic significance of VEGF immunohistochemical expression and tumor angiogenesis in head and neck squamous cell carcinoma. J Cancer Res Clin Oncol (2005) 1.23
Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. Breast Cancer Res (2003) 1.21
Discrepancies in current practice of pathological evaluation of sentinel lymph nodes in breast cancer. Results of a questionnaire based survey by the European Working Group for Breast Screening Pathology. J Clin Pathol (2004) 1.19
The favourable prognostic value of oestrogen receptor beta immunohistochemical expression in breast cancer. J Clin Pathol (2004) 1.18
Association between a germline OCA2 polymorphism at chromosome 15q13.1 and estrogen receptor-negative breast cancer survival. J Natl Cancer Inst (2010) 1.17
Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer. Br J Cancer (2003) 1.17
Does size matter? Comparison study between MRI, gross, and microscopic tumor sizes in breast cancer in lumpectomy specimens. Int J Clin Exp Pathol (2010) 1.17
Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays. J Clin Pathol (2006) 1.13
PET-CT for radiotherapy treatment planning and response monitoring in solid tumors. Nat Rev Clin Oncol (2011) 1.11
Complete sectioning of axillary sentinel nodes in patients with breast cancer. Analysis of two different step sectioning and immunohistochemistry protocols in 246 patients. J Clin Pathol (2002) 1.11
Relationship between the expression of cyclooxygenase 2 and MDR1/P-glycoprotein in invasive breast cancers and their prognostic significance. Breast Cancer Res (2005) 1.07
Testing the feasibility of intra-operative sentinel lymph node touch imprint cytology. Ann R Coll Surg Engl (2009) 1.06
Flotillin-2 is associated with breast cancer progression and poor survival outcomes. J Transl Med (2013) 1.04
p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer. Breast Cancer Res (2006) 1.03
Metastatic canine mammary carcinomas can be identified by a gene expression profile that partly overlaps with human breast cancer profiles. BMC Cancer (2010) 1.03
Computerized classification of intraductal breast lesions using histopathological images. IEEE Trans Biomed Eng (2011) 1.02
A multimarker QPCR-based platform for the detection of circulating tumour cells in patients with early-stage breast cancer. Br J Cancer (2011) 1.02
Modeling the effect of tumor size in early breast cancer. Ann Surg (2005) 1.01
Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors. Breast Cancer Res Treat (2008) 1.00
Metastasis detection in sentinel lymph nodes: comparison of a limited widely spaced (NSABP protocol B-32) and a comprehensive narrowly spaced paraffin block sectioning strategy. Am J Surg Pathol (2009) 1.00
The fragile X protein binds mRNAs involved in cancer progression and modulates metastasis formation. EMBO Mol Med (2013) 0.99
Prognostic analysis of tumour angiogenesis, determined by microvessel density and expression of vascular endothelial growth factor, in high-risk primary breast cancer patients treated with high-dose chemotherapy. Br J Cancer (2007) 0.99
Gene signatures of breast cancer progression and metastasis. Breast Cancer Res (2011) 0.99
Pathogenesis, prevention, diagnosis and treatment of breast cancer. World J Clin Oncol (2014) 0.98
Estrogen receptor alpha expression in ovarian cancer predicts longer overall survival. Pathol Oncol Res (2011) 0.98
Axillary lymph node status, adjusted for pathologic complete response in breast and axilla after neoadjuvant chemotherapy, predicts differential disease-free survival in breast cancer. Curr Oncol (2013) 0.98
Multivariate analysis of oestrogen receptor alpha, pS2, metallothionein and CD24 expression in invasive breast cancers. Br J Cancer (2006) 0.97
Expression profiling of human renal carcinomas with functional taxonomic analysis. BMC Bioinformatics (2002) 0.97
p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: a cohort study. Int J Clin Oncol (2006) 0.97
Comparative evaluation of the modified Scarff-Bloom-Richardson grading system on breast carcinoma aspirates and histopathology. Cytojournal (2012) 0.97
Squalene epoxidase, located on chromosome 8q24.1, is upregulated in 8q+ breast cancer and indicates poor clinical outcome in stage I and II disease. Br J Cancer (2008) 0.97
Immunophenotypic features of tumor infiltrating lymphocytes from mammary carcinomas in female dogs associated with prognostic factors and survival rates. BMC Cancer (2010) 0.97
Micrometastasis in the sentinel lymph node of breast cancer does not mandate completion axillary dissection. Ann Surg (2004) 0.96
Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype. BMC Res Notes (2012) 0.96
Increased expression levels of WAVE3 are associated with the progression and metastasis of triple negative breast cancer. PLoS One (2012) 0.96
Ki-67 expression in primary breast carcinomas and their axillary lymph node metastases: clinical implications. Virchows Arch (2007) 0.95
Transducin (β)-like 1 X-linked receptor 1 promotes proliferation and tumorigenicity in human breast cancer via activation of beta-catenin signaling. Breast Cancer Res (2014) 0.95
Predictive and prognostic factors in locally advanced breast cancer: effect of intratumoral FOXP3+ Tregs. Clin Exp Metastasis (2013) 0.94
Clinical relevance of lymph node ratio in breast cancer patients with one to three positive lymph nodes. Br J Cancer (2013) 0.94
Impact of internal mammary lymph node drainage identified by preoperative lymphoscintigraphy on outcomes in patients with stage I to III breast cancer. Cancer (2012) 0.93
Node retrieval in axillary lymph node dissections: recommendations for minimum numbers to be confident about node negative status. J Clin Pathol (2004) 0.93
Parameters of dynamic contrast-enhanced MRI as imaging markers for angiogenesis and proliferation in human breast cancer. Med Sci Monit (2015) 0.92
Analysis of EpCAM positive cells isolated from sentinel lymph nodes of breast cancer patients identifies subpopulations of cells with distinct transcription profiles. Breast Cancer Res (2011) 0.92
Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer. Br J Cancer (2010) 0.91
Patient and process factors associated with late-stage breast cancer diagnosis in Safety-Net patients: a pilot prospective study. Ann Surg Oncol (2012) 0.91
Genetic polymorphisms in telomere pathway genes, telomere length, and breast cancer survival. Breast Cancer Res Treat (2012) 0.90
New trends of immunohistochemistry for making differential diagnosis of breast lesions. Med Mol Morphol (2006) 0.90
Lymph vascular invasion in invasive mammary carcinomas identified by the endothelial lymphatic marker D2-40 is associated with other indicators of poor prognosis. BMC Cancer (2008) 0.89
Assessment of lesions coexisting with various grades of ductal intraepithelial neoplasia of the breast. Virchows Arch (2004) 0.89
14-3-3ζ as a predictor of early time to recurrence and distant metastasis in hormone receptor-positive and -negative breast cancers. Breast Cancer Res Treat (2012) 0.88
Mechanical phenotyping of breast cancer using MEMS: a method to demarcate benign and cancerous breast tissues. Lab Chip (2014) 0.88
Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes. J Cancer (2016) 0.87
Different Expression of Extracellular Signal-Regulated Kinases (ERK) 1/2 and Phospho-Erk Proteins in MBA-MB-231 and MCF-7 Cells after Chemotherapy with Doxorubicin or Docetaxel. Iran J Basic Med Sci (2012) 0.87
Prognostic role of c-met expression in breast cancer patients. Rep Pract Oncol Radiother (2011) 0.87
Differential expression of HIF-1α in CD44+CD24-/low breast ductal carcinomas. Diagn Pathol (2011) 0.87
Allogeneic tumor cell vaccines: the promise and limitations in clinical trials. Hum Vaccin Immunother (2013) 0.87
Vascular measurements correlate with estrogen receptor status. BMC Cancer (2014) 0.87
The clinical impact of mean vessel size and solidity in breast carcinoma patients. PLoS One (2013) 0.86
ERM/Rho protein expression in ductal breast cancer: a 15 year follow-up. Cell Oncol (Dordr) (2013) 0.85
Landmark trials affecting the surgical management of invasive breast cancer. Surg Clin North Am (2013) 0.85
Prediction of axillary lymph node metastasis in primary breast cancer patients using a decision tree-based model. BMC Med Inform Decis Mak (2012) 0.84
Evaluation of serum vascular endothelial growth factor (VEGF) and microvessel density (MVD) as prognostic indicators in carcinoma breast. J Cancer Res Clin Oncol (2008) 0.84
Intraoperative imprint cytologic evaluation of sentinel lymph nodes for lobular carcinoma of the breast. Ann Surg (2004) 0.84
The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer. Br J Cancer (2002) 0.84
The clinicopathological evaluation of the breast cancer patients with brain metastases: predictors of survival. Clin Exp Metastasis (2012) 0.84
Supervised automated microscopy increases sensitivity and efficiency of detection of sentinel node micrometastases in patients with breast cancer. J Clin Pathol (2004) 0.83
Lobular neoplasia: frequency and association with other breast lesions. Diagn Pathol (2011) 0.83
Development and validation of a prognostic nomogram based on the log odds of positive lymph nodes (LODDS) for breast cancer. Oncotarget (2016) 0.83
Prognostic significance of immunohistochemical expression of p53 gene product in operable breast cancer. Cancer Res Treat (2006) 0.83
A hybrid machine learning-based method for classifying the Cushing's Syndrome with comorbid adrenocortical lesions. BMC Genomics (2008) 0.83
Does shear wave ultrasound independently predict axillary lymph node metastasis in women with invasive breast cancer? Breast Cancer Res Treat (2013) 0.83
Immunohistochemical detection improves the prognostic value of lymphatic and blood vessel invasion in primary ductal breast cancer. BMC Cancer (2014) 0.82
Expression of the cell cycle regulatory proteins p34cdc2, p21waf1, and p53 in node negative invasive ductal breast carcinoma. Mol Pathol (2003) 0.82
The role of tumor hypoxia in MUC1-positive breast carcinomas. Virchows Arch (2011) 0.82
Human kallikrein gene 13 (KLK13) expression by quantitative RT-PCR: an independent indicator of favourable prognosis in breast cancer. Br J Cancer (2002) 0.82
Detection of MAGE-A3 in breast cancer patients' sentinel lymph nodes. Br J Cancer (2001) 0.82
[Recommendations for the handling and oncologic pathology report of lymph node specimens submitted for evaluation of metastatic disease in gynecologic malignancies]. Pathologe (2005) 0.81
Detected, yet not Diagnosed - Breast Cancer Screening with MRI Mammography in High-Risk Women. Breast Care (Basel) (2012) 0.81
Heterologous tissue culture expression signature predicts human breast cancer prognosis. PLoS One (2007) 0.81
Semi-automated evaluation of Ki-67 index in invasive ductal carcinoma of the breast. Oncol Lett (2013) 0.81
Imaging lymphatic system in breast cancer patients with magnetic resonance lymphangiography. PLoS One (2013) 0.81
Tumor characteristics of breast cancer in predicting axillary lymph node metastasis. Med Sci Monit (2014) 0.81
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88
Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol (1998) 11.84
Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol (1999) 11.18
The sentinel node in breast cancer--a multicenter validation study. N Engl J Med (1998) 8.48
Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell (1997) 8.28
Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med (1985) 7.22
Acute enterocolitis in a human being infected with the protozoan Cryptosporidium. Gastroenterology (1976) 6.15
REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer (2005) 4.85
Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst (1993) 4.45
Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst (1994) 4.28
BRCA1 is secreted and exhibits properties of a granin. Nat Genet (1996) 4.26
Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst (2000) 4.26
Junction adhesion molecule is a receptor for reovirus. Cell (2001) 4.00
Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J Natl Cancer Inst (1995) 3.96
Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer (1985) 3.92
c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med (1994) 3.89
Aberrant subcellular localization of BRCA1 in breast cancer. Science (1995) 3.61
Benign transport of breast epithelium into axillary lymph nodes after biopsy. Am J Clin Pathol (2000) 3.55
Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med (1992) 3.55
Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science (1996) 3.54
Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. J Natl Cancer Inst (1996) 3.45
Cathepsin D and prognosis in breast cancer. N Engl J Med (1990) 3.43
Interobserver reproducibility in the diagnosis of ductal proliferative breast lesions using standardized criteria. Am J Surg Pathol (1992) 3.39
A prospective study of benign breast disease and the risk of breast cancer. JAMA (1992) 3.29
2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol (2001) 3.25
Introduction of a mu immunoglobulin gene into the mouse germ line: specific expression in lymphoid cells and synthesis of functional antibody. Cell (1984) 3.24
Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res (2001) 3.18
Creation of "amyloid" fibrils from Bence Jones proteins in vitro. Science (1971) 3.14
Laparoscopic cholecystectomy. Treatment of choice for symptomatic cholelithiasis. Ann Surg (1991) 3.11
Long-term risk of breast cancer in women with fibroadenoma. N Engl J Med (1994) 3.09
Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol (2001) 3.06
Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol (1999) 3.04
Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol (1995) 2.96
HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol (1989) 2.96
A Pluto-like radius and a high albedo for the dwarf planet Eris from an occultation. Nature (2011) 2.91
Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet (1995) 2.91
Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol (1994) 2.77
Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med (1991) 2.77
Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat Med (1995) 2.74
The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med (1996) 2.74
Growth and metastasis of surgical specimens of human breast carcinomas in SCID mice. Cancer J Sci Am (2006) 2.68
Myocardial changes associated with cardiogenic shock. N Engl J Med (1971) 2.67
Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin Cancer Res (1999) 2.55
Columnar alteration with prominent apical snouts and secretions: a spectrum of changes frequently present in breast biopsies performed for microcalcifications. Am J Surg Pathol (1998) 2.53
HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry. A study of interlaboratory agreement. Am J Clin Pathol (2000) 2.53
Speech perception as a function of electrical stimulation rate: using the Nucleus 24 cochlear implant system. Ear Hear (2000) 2.51
Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst (1994) 2.50
A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: Gastrointestinal Tumor Study Group Protocol 6584. J Clin Oncol (1991) 2.46
Radial scars in benign breast-biopsy specimens and the risk of breast cancer. N Engl J Med (1999) 2.45
Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma. Hum Pathol (1993) 2.42
Evaluation of a new spectral peak coding strategy for the Nucleus 22 Channel Cochlear Implant System. Am J Otol (1994) 2.37
Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer (1996) 2.33
DACRYO-CYSTO-RHINOSTOMY. Br J Ophthalmol (1946) 2.32
Clinical experience over 48 years with pheochromocytoma. Ann Surg (1999) 2.32
Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol (1999) 2.32
Loss of expression of transforming growth factor beta type II receptor correlates with high tumour grade in human breast in-situ and invasive carcinomas. Histopathology (2000) 2.27
Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res (2000) 2.24
The relationship between shaved margin and inked margin status in breast excision specimens. Cancer (1997) 2.22
Expression of mitoses per thousand cells and cell density in breast carcinomas: a proposal. Hum Pathol (1992) 2.18
The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther (2007) 2.18
Intraductal carcinoma of the breast: follow-up after biopsy only. Cancer (1982) 2.17
HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res (1990) 2.14
The measurement and therapeutic implications of circulating tumour cells in breast cancer. Br J Cancer (2006) 2.14
Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res (1985) 2.13
Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol (1987) 2.12
Utilization of sialic acid as a coreceptor enhances reovirus attachment by multistep adhesion strengthening. J Biol Chem (2000) 2.12
Mammary tumor suppression by transforming growth factor beta 1 transgene expression. Proc Natl Acad Sci U S A (1995) 2.07
Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst (1998) 2.06
Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol (1992) 2.05
Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers. J Natl Cancer Inst (1992) 2.05
American Joint Committee on Cancer prognostic factors consensus conference. Cancer (1999) 2.02
Balloon dilatation of calcific aortic stenosis in elderly patients: postmortem, intraoperative, and percutaneous valvuloplasty studies. Circulation (1986) 2.00
p53 antigen loss in stored paraffin slides. N Engl J Med (1995) 1.99
Infiltrating lobular carcinoma of the breast. Histopathology (1982) 1.98
Amyloid, amyloidosis, and amyloidogenesis. Int Rev Exp Pathol (1976) 1.97
A transgenic immunoglobulin mu gene prevents rearrangement of endogenous genes. Cell (1985) 1.96
Heat shock protein hsp70 in patients with axillary lymph node-negative breast cancer: prognostic implications. J Natl Cancer Inst (1993) 1.95
How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst (1990) 1.95
Pathologic predictors of early local recurrence in Stage I and II breast cancer treated by primary radiation therapy. Cancer (1984) 1.95